Background: The short-term efficacy and safety of percutaneous embolization for the treatment of hemodynamically unstable patients with grade 5 renal injuries secondary to blunt trauma has been previously established; however, there has been no published intermediate-term follow-up. The purpose of this study is to report intermediate-term follow-up and complications for this treatment modality.
Methods: A retrospective study was performed to determine intermediate-term outcomes in an observational cohort of patients who underwent percutaneous embolization for the management of grade 5 blunt renal trauma. Demographic and perioperative data were obtained. Follow-up was performed via mail and/or phone questionnaires.
Results: Between October 2004 and July 2008, 10 hemodynamically unstable patients with grade 5 blunt renal trauma were treated with percutaneous embolization. Mean age of the cohort was 29 years (range, 5-50). Mean follow-up via phone and/or mail questionnaires was 2.7 years (1.5-5.1 years). One patient reported a new diagnosis of hypertension, which is well controlled by a single antihypertensive medication. There were no reported complications of refractory hypertension, altered renal function, new urolithiasis, chronic pain, urine leak, arteriovenous fistula, or pseudoaneurysm. No other procedures were required after the initial embolization for their renal trauma.
Conclusions: Management of grade 5 renal injuries with percutaneous embolization is safe and is not associated with intermediate-term adverse events.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/TA.0b013e3181e5407a | DOI Listing |
Int J Med Sci
January 2025
Department of Cardiology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, People's Republic of China.
Coronary microembolization (CME) is defined as atherosclerotic plaque erosion, spontaneous rupture, or rupture of the plaque while undergoing interventional therapy resulting in the formation of tiny emboli that obstruct the coronary microcirculatory system. For percutaneous coronary intervention, CME is a major complication, with a periprocedural incidence of up to 25%. Recent studies have demonstrated that regulatory cell death (RCD) exerts a profound influence on CME through its modulation of inflammatory responses, oxidative stress, cell death, and angiogenesis.
View Article and Find Full Text PDFThe broad spectrum of clinical manifestations caused by peripheral arterial disease [PAD] and the morphologic heterogeneity of associated atherosclerotic lesions present a considerable management challenge. Endovascular interventions are recognized an effective treatment for PAD. Within this revascularization strategy the role of atherectomy debulking modalities continue to evolve.
View Article and Find Full Text PDFOper Orthop Traumatol
December 2024
Department for Orthopaedic and Trauma Surgery, Lucerne Cantonal Hospital LUKS, Spitalstrasse, Lucerne, Switzerland.
Objective: To maximize local tumor control, stabilize affected bones, and preserve or replace joints with minimal interventional burden, thereby enhancing quality of life for empowered living.
Indications: Suitable for patients with bone metastases, particularly those with severe pain and/or fractures and appropriate life expectancy.
Contraindications: In primary bone tumors, refer to the sarcoma surgery team for evaluation of wide resection.
J Cardiovasc Dev Dis
December 2024
Cardiology Department, Mother and Child Health Institute of Serbia, 11070 Belgrade, Serbia.
Background: The vertical vein (VV) ligation during the total anomalous pulmonary venous return (TAPVR) correction is still controversial. Our study aimed to define the potential risk factors for VV persistence and their percutaneous occlusion.
Methods: The retrospective cohort study included 40 patients (26 males) with TAPVR treated at the tertiary referral center from 2005 to 2024.
Front Med (Lausanne)
December 2024
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
Bacterial liver abscesses commonly occur in patients with immune deficiencies such as diabetes, post-chemotherapy, or post-immunosuppressive therapy. The recommended treatment for liver abscesses exceeding 5 cm in a diameter is anti-infection therapy combined with percutaneous catheter drainage. Complications may include local spread to adjacent tissues or organs and thrombosis of the liver and portal veins.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!